DelMar Pharmaceuticals, Inc. (DMPI) Director Buys $16,200.00 in Stock
DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) Director John K. Bell bought 20,000 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were purchased at an average price of $0.81 per share, with a total value of $16,200.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) opened at $0.86 on Monday. DelMar Pharmaceuticals, Inc. has a 1-year low of $0.78 and a 1-year high of $5.39.
DelMar Pharmaceuticals (NASDAQ:DMPI) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.01). analysts anticipate that DelMar Pharmaceuticals, Inc. will post -0.61 earnings per share for the current fiscal year.
An institutional investor recently bought a new position in DelMar Pharmaceuticals stock. Franklin Resources Inc. acquired a new position in DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,076,923 shares of the company’s stock, valued at approximately $2,477,000. 8.26% of the stock is currently owned by institutional investors and hedge funds.
DMPI has been the subject of a number of analyst reports. Dawson James reiterated a “buy” rating on shares of DelMar Pharmaceuticals in a report on Tuesday, August 8th. Maxim Group restated a “hold” rating on shares of DelMar Pharmaceuticals in a report on Monday, September 11th. Finally, HC Wainwright set a $12.00 price objective on shares of DelMar Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 16th.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
Receive News & Stock Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.